61-52-9Relevant articles and documents
Binding properties of dipropyltryptamine at the human 5-HT1a receptor
Thiagaraj, Harish V.,Russo, Ethan B.,Burnett, Andrea,Goldstein, Eric,Thompson, Charles M.,Parker, Keith K.
, p. 193 - 199 (2005)
Dipropyltryptamine (DPT) is a synthetic indolealkylamine first characterized in the 1960s. Largely forgotten since the discovery of multiple serotonin receptor subtypes, some of the properties of DPT at the cloned human 5-HT1a receptor are described here. When [3H]8-OH-DPAT is bound to the receptor, DPT inhibits the interaction with an IC50 of 0.1 μmol/l. This interaction is shown to be competitive when double-reciprocal plots of the DPT/agonist interaction are analyzed. DPT's effects in the signal transduction system are complex. While DPT alone (0.1-1,000 μmol/l) activates Gi when both cAMP and γ-S-GTP incorporation are measured, in the presence of 5-HT (0.1-10 μmol/l), DPT blocks the agonist effect. In combination, the findings suggest that DPT is a moderate affinity partial agonist at the human 5-HT1a receptor. These results provide evidence that DPT has potential as a versatile experimental tool at 5-HT1a receptors. Copyright
Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus
Qu, Shi-Jin,Wang, Gui-Feng,Duan, Wen-Hu,Yao, Shan-Yan,Zuo, Jian-Ping,Tan, Chang-Heng,Zhu, Da-Yuan
experimental part, p. 3120 - 3127 (2011/06/24)
A series of tryptamine derivatives were synthesized and evaluated for their anti-hepatitis B virus (HBV) activity and cytotoxicity in the HepG2.2.15 cell line. The preliminary SAR was discussed. Compounds 2e and 4a showed potent antiviral activity (IC50 = 0.4 and 50 = 40.6 and >25 μM, respectively).